Abstract
Here we describe a method using mass spectrometry to characterize and quantify immuno-enriched α-synuclein forms from biochemically fractionated brain tissue.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG (2010) Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 4(5):683–699
Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66(2):200–208
Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69(11):1445–1452
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG (2011) Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10(3):230–240
Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K et al (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450(3):332–335
Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ et al (2014) Increased CSF alpha-synuclein levels in Alzheimer’s disease: correlation with tau levels. Alzheimers Dement 10(5 Suppl):S290–S298
Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26(3):213–216
Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Bostrom F et al (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8(1):e53250
Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K (2013) The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 8(11):e81654
Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, Steinacker P et al (2016) Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer’s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol Cell Proteomics 15(10):3126–3138
Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L et al (2014) Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 6(3):25
Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T et al (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20):1766–1772
Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3(10):812–818
Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C et al (2017) Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 74(2):163–172
Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L et al (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5(2):55–59
Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D et al (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133(Pt 3):713–726
Uchihara T, Giasson BI (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131(1):49–73
Acknowledgments
Work in the authors’ laboratories is supported by the Michael J. Fox Foundation (MJFF) for Parkinson’s Research, the Swedish Research Council, the European Research Council, the Knut and Alice Wallenberg Foundation, the Torsten Söderberg Foundation, the Eivind and Elsa K:Son Sylvans Foundation, the Märtha and Gustaf Ågrens Foundation, the Olav Thon Foundation, Swedish State Support for Clinical Research (ALFGBG), Alzheimerfonden, Stiftelsen för Gamla Tjänarinnor, and Frimurarestiftelsen.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Brinkmalm, A., Öhrfelt, A., Bhattacharjee, P., Zetterberg, H. (2019). Detection of α-Synuclein in Biological Samples Using Mass Spectrometry. In: Bartels, T. (eds) Alpha-Synuclein. Methods in Molecular Biology, vol 1948. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9124-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9124-2_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9123-5
Online ISBN: 978-1-4939-9124-2
eBook Packages: Springer Protocols